Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: Urology. 2011 Oct 11;78(6):1257–1262. doi: 10.1016/j.urology.2011.07.1413

Table 1.

Means (standard deviations) of NIF, CMG and PFS urodynamic measures at baseline, 24 months and the difference of the two by success status (success/failure).

Success Failure
n Baseline 24 Months Difference: 24 Mos – Baseline P-value (change over time)* n Baseline 24 Months Difference: 24 Mos – Baseline P-value (change over time)** P-value (time by success status interaction)***
NIF Qmax 150 24.53
(10.19)		 20.12
(9.32)		 -4.41
(11.61)		 <0.001 216 26.02
(12.41)		 22.65
(12.34)		 -3.37
(13.83)		 <0.001 0.45
NIF Volume 150 320.12
(156.10)		 324.77
(146.93)		 4.65
(192.46)		 0.77 216 311.69
(138.80)		 308.93
(135.16)		 -2.76
(153.83)		 0.79 0.68
NIF PVR 150 27.79
(35.85)		 31.01
(44.39)		 3.23
(54.23)		 0.47 216 25.05
(34.37)		 33.24
(45.47)		 8.19
(47.54)		 0.012 0.35
MCC 165 411.18
(146.95)		 412.10
(122.11)		 0.92
(125.14)		 0.92 222 390.08
(128.17)		 377.51
(125.63)		 -12.57
(141.13)		 0.19 0.33
Compliance 125 30.71
(196.42)		 48.11
(155.53)		 17.40
(266.59)		 0.47 168 73.57
(175.90)		 43.85
(130.19)		 -29.72
(225.89)		 0.09 0.10
PFS Qmax 72 19.72
(7.38)		 16.70
(7.72)		 -3.03
(7.87)		 0.002 96 21.50
(9.71)		 18.11
(9.03)		 -3.39
(9.14)		 <0.001 0.79
Pdet@Qmax 71 15.56
(11.93)		 26.62
(23.41)		 11.06
(23.10)		 <0.001 95 19.45
(10.64)		 22.60
(13.80)		 3.15
(15.46)		 0.050 0.009
BOOI 71 -24.07
(19.12)		 -6.91
(31.21)		 17.16
(31.15)		 <0.001 95 -23.56
(23.79)		 -13.82
(24.39)		 9.74
(25.17)		 <0.001 0.09
*

P-value associated with test of change between baseline and 24 months (among successes).

**

P-value associated with test of change between baseline and 24 months (among failures).

***

P-value associated with test of whether mean change between baseline and 24 months differs by success/failure status